Abstract: A new compound composition that is free of a side effect to a liver and used for alleviating the toxicity of an acetaminophen (APAP) medicament to the liver. The compound composition comprises (a) a pharmaceutically effective amount of acetaminophen and (b) a frequently-used safe and pharmaceutically acceptable excipient that can be combined with one or more than two medicaments that can reduce the toxicity of a drug via liver enzyme CYP2E1 metabolism to the liver.

Abstract: A new compound composition that is free of a side effect to a liver and used for alleviating the toxicity of an acetaminophen (APAP) medicament to the liver. The compound composition comprises (a) a pharmaceutically effective amount of acetaminophen and (b) a frequently-used safe and pharmaceutically acceptable excipient that can be combined with one or more than two medicaments that can reduce the toxicity of a drug via liver enzyme CYP2E1 metabolism to the liver.

Abstract: The present invention relates to compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof. The present compound is represented by Formula (II), which has the formula: R1—O—X—(CH2)m—X—O—R2, wherein: each X is —C(?O)—; R1 is a C1-C18 alkyl polyol; R2 is a saccharide group of formula (G)p; G is a monosaccharide residue, where (i) at least one of the —OH groups in (G)p is substituted by a halogen atom, and (ii) the saccharide group of formula (G)p is linked to —O— through a —CH2 group; p is 1 or 2; and m is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

Abstract: The present invention relates to compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof. The present compound is represented by Formula (II), which has the formula: R1—O—X—(CH2)m—X—O—R2, wherein: each X is —C(?O)—; R1 is a C1-C18 alkyl polyol: R2 is a saccharide group of formula (G)p; G is a monosaccharide residue, where (i) at least one of the —OH groups in (G)p is substituted by a halogen atom, and (ii) the saccharide group of formula (G)p is linked to —O— through a —CH2 group; p is 1 or 2; and m is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

Abstract: A galactose oral composition having galactose, an antioxidant and a buffer. The galactose oral composition contains 1%-80% by weight of galactose. The antioxidant is selected from Vitamin A, Vitamin C, Vitamin E, Ethylenediaminetetraacetic acid (EDTA), sodium bisulfite, flavonoids, polyphenols, Diethylenetriaminepentaacetic acid (DTPA), and NTA-Nitrilotriacetate acid (NTA). The buffer is selected from ascorbic acid buffer, citrate buffer, phosphate buffer, acetate buffer, carbonate buffer, and triethanolamine buffer. The galactose oral composition can be applied to detect individual galactose metabolic ability to assess liver function.

Abstract: The present invention relates to methods and compositions for preventing or treating fatty liver, protecting liver function or ameliorating liver diseases caused by fatty liver or other associated disorders.

Abstract: The present invention relates to methods and compositions for preventing, reducing or eradicating toxicity caused by acetaminophen (APAP). Specifically, the toxicity is nephrotoxicity and/or hepatotoxicity.

Abstract: A galactose oral composition having galactose, an antioxidant and a buffer. The galactose oral composition contains 1%-80% by weight of galactose. The antioxidant is selected from Vitamin A, Vitamin C, Vitamin E, Ethylenediaminetetraacetic acid (EDTA), sodium bisulfite, flavonoids, polyphenols, Diethylenetriaminepentaacetic acid (DTPA), and NTA-Nitrilotriacetate acid (NTA). The buffer is selected from ascorbic acid buffer, citrate buffer, phosphate buffer, acetate buffer, carbonate buffer, and triethanolamine buffer. The galactose oral composition can be applied to detect individual galactose metabolic ability to assess liver function.

Abstract: A galactose rapid detection system has a galactose composition including a galactose, a buffer solution and an 0-99% antioxidant, which enters a human body after metabolism and produces a biological sample; a test strip or a filter paper, comprising an enzyme, the enzyme would react with the biological sample producing a electrochemical information ;a meter including a power supply unit for providing a signal; a connector for receiving the signal provided by the power supply unit, transmitting the signal to the test strip or the filter paper, wherein the signal reacting with the electrochemical information produce a corresponding response signal, and the connector transmit the corresponding response signal to the meter; a calculation unit for calculating the corresponding response signal; an A/D convertor for receiving the corresponding response signal from the calculation unit, transforming the corresponding response signal into a digital reaction signal calculated by the calculation unit; and a processor fo

Abstract: The present invention relates to pharmaceutical compositions/combination/kit and methods for treating pain, which provide synergistic analgesic effects and less side effects.

Abstract: The present invention relates to compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof. The present compound is represented by Formula (II), which has the formula: R1—O—X—(CH2)m—X—O—R2, wherein: each X is —C(?O)—; R1 is a C1-C18 alkyl polyol: R2 is a saccharide group of formula (G)p; G is a monosaccharide residue, where (i) at least one of the —OH groups in (G)p is substituted by a halogen atom, and (ii) the saccharide group of formula (G)p is linked to —O— through a —CH2 group; p is 1 or 2; and m is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

Abstract: The present invention relates to compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof. The present compound is represented by Formula (II), which has the formula: R1—O—X—(CH2)m—X—O—R2, wherein: each X is —C(?O)—; R1 is a C1-C18 alkyl polyol; R2 is a saccharide group of formula (G)p; G is a monosaccharide residue, where (i) at least one of the —OH groups in (G)p is substituted by a halogen atom, and (ii) the saccharide group of formula (G)p is linked to —O— through a CH2 group; p is 1 or 2; and m is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

Abstract: A new compound composition that is free of a side effect to a liver and used for alleviating the toxicity of an acetaminophen (APAP) medicament to the liver. The compound composition comprises (a) a pharmaceutically effective amount of acetaminophen and (b) a frequently-used safe and pharmaceutically acceptable excipient that can be combined with one or more than two medicaments that can reduce the toxicity of a drug via liver enzyme CYP2E1 metabolism to the liver.

Abstract: The present invention relates to a composition and method for preventing or treating fatty pancreas, or ameliorating a pancreas disease caused by fatty pancreas, diabetes mellitus or other related disorders.

Abstract: The present invention relates to compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof.

Abstract: The present invention relates to methods and compositions for preventing or treating fatty liver, protecting liver function or ameliorating liver diseases caused by fatty liver or other associated disorders.

Abstract: This invention is to provide multiple specific inhibitors of cytochrome P450 isozyme CYP2C9. These inhibitors can be derived from any combinations with the following compounds including: Tamarixetin, Formononetin, isoliquritigenin, Phloretin, luteolin, Quercitrin, quercetin, myricetin, Wongonin, Puerarin, Genistein, Nordihydroguaiaretic acid, Narigenin, Capillarisin, Chrysin, Fisefin, eriodictyol, 6-Gingerol, Isorhamneti, isoquercitrin, Morin, (+)-Taxifolin, isovitexin, 3-Phenylpropyl Acetate, Oleanolic acid, ursolic acid, ?-Myrcene, cinnamic acid, Luteolin-7-Glucoside, Liquiritin, (+)Limonene, Homoorientin, Swertiamarin, Embelin, Daidzein, Poncirin, (?)-Epicatechin, ergosterol. These natural products can be used to enhance the bioavailability of therapeutic agents (drugs).

Abstract: This invention is to provide multiple specific inhibitors of cytochrome P450 isozyme CYP2C9. These inhibitors can be derived from any combinations with the following compounds including: Tamarixetin, Formononetin, isoliquritigenin, Phloretin, luteolin, Quercitrin, quercetin, myricetin, Wongonin, Puerarin, Genistein, Nordihydroguaiaretic acid, Narigenin, Capillarisin, Chrysin, Fisefin, eriodictyol, 6-Gingerol, Isorhamneti, isoquercitrin, Morin, (+)-Taxifolin, isovitexin, 3-Phenylpropyl Acetate, Oleanolic acid, ursolic acid, ?-Myrcene, cinnamic acid, Luteolin-7-Glucoside, Liquiritin, (+) Limonene, Homoorientin, Swertiamarin, Embelin, Daidzein, Poncirin, (?)-Epicatechin, ergosterol. These natural products can be used to enhance the bioavailability of therapeutic agents (drugs).

Abstract: The present invention provides cytochrome P450 3A (CYP3A) inhibitors and enhancers. Examples of the CYP3A inhibitors include free bases or pharmacologically acceptable salts of at least one of the following compounds: ?-naphthoflavone, ?-naphthoflavone, apigenin, baicalein, ?-myrcene, catechin, 3-phenylpropyl acetate, formononetin, gallic acid, hesperetin, hesperidin, isoquercitrin, lauryl alcohol, luteolin, luteolin-7-glycoside, narigin, nordihydroguaiaretic acid, quercitrin, swertiamarin, terpineol, and trans-cinnamaldehyde. Examples of the CYP3A enhancers include free bases or pharmacologically acceptable salts of at least one of the following compounds: apigenin, formononetin, and luteolin-7-glycoside. The CYP3A inhibitors can be used, alone or co-administered with a drug, to improve the drug bioavailability.

Abstract: The present invention provides orally administered pharmaceutical compositions which contains an effective amount of free base or pharmaceutically acceptable salts of nalbuphine and/or nalbuphine ester, an oily substance, and a solubility-assisting agent. The oily substance is preferably sesame oil. The solubility-assisting agent is preferably benzyl benzoate. The pharmaceutical composition is useful as an analgesic. The compositions achieves a much higher bioavailability rate and yields much longer lasting effects on nalbuphine than other nalbuphine products currently in the market.